WASHINGTON and SUN CITY WEST, Ariz., May 16 /PRNewswire/ -- Gentag, Inc. and The CORE Institute(R) are pleased to announce a joint collaborative effort to develop and market RFID Skin Patches for Medical Applications in the area of Orthopedics.
The aim of the joint program is to facilitate post surgery monitoring applications by physicians and patients using RFID enabled cell phones under Gentag, Altivera and CORE patents. Specifically, physicians will be able to monitor the status of damaged tissues using temperature, pressure, and other sensors. Additionally, patients will be able to self-monitor their recovery from the comfort of their own homes. The technology platform uses RFID enabled cell phones, PDAs or wireless laptops that allow remote monitoring by physicians and hospitals, particularly during the critical first 24 hours post injury or surgery.
"We believe that cell phones are the ideal tools to enable consumer-based diagnostics and that The CORE Institute(R) has identified a unique market to illustrate how low cost RFID technologies combined with cell phones can save costs in medicine," announced Dr. John Peeters the founder of Gentag. "We are very pleased to have signed this agreement and look forward to working with CORE and their partners."
"The CORE Institute(R) believes that this new technology platform will not only decrease the cost of health care delivery, but more importantly will markedly improve patient safety and outcomes due to earlier and more accurate diagnosis of changes in a patient's condition."
Gentag, Inc. and Altivera, LLC are IP and technology development companies focusing on the development of innovative, low cost wireless technologies to improve health worldwide. The company owns unique intellectual property relating to cell phone sensor combinations and wireless sensor networks.
The CORE Institute(R) is a private medical practice with offices throughout Arizona providing a wide range of orthopedic services including patient care, research, community service and medical education. Their clinical and research team is dedicated to pioneering research that expands orthopedic knowledge and continues to deliver state-of-the-art care.
For media inquiries, please contact Marc Onigman at (617) 413-2830 (Gentag) or Marc C Jacofsky, Director of Intellectual Property Development, The CORE Institute at (623) 537-5642.
For more information, visit http://www.thecoreinstitute.com/ and http://www.gentag.com/
CONTACT: Marc Onigman of Gentag, Inc., +1-617-413-2830, or Marc C.Jacofsky, Director of Intellectual Property Development of The COREInstitute, +1-623-537-5642